Commentary

Article

State of Science Summit: Chaired by Kathryn Mileham, MD, FACP | Atrium Health Levine Cancer Institute

In Partnership With:

State of Science Summit: Chaired by Kathryn Mileham, MD, FACP | Atrium Health Levine Cancer Institute

State of Science Summit: Chaired by Kathryn Mileham, MD, FACP | Atrium Health Levine Cancer Institute

Speakers

  • Daniel Carrizosa, MD, MS l Atrium Health Levine Cancer Institute
  • Christopher Pallas, MD | Atrium Health Levine Cancer Institute
  • Daniel Haggstrom, MD | Atrium Health Levine Cancer Institute
  • John Heinzerling, MD | Atrium Health Levine Cancer Institute
  • Jeffrey A. Hagen, MD l Atrium Health Levine Cancer Institute

Topics

  • EGFRm NSCLC: Adjuvant to Metastatic
  • Treating Exon 20 Mutations in NSCLC
  • KRAS-Targeted Therapies in NSCLC
  • Current and Emerging Standards in SCLC
  • Updates in Radiation Utilization in all stages of NSCLC and SCLC
  • Early-Stage NSCLC: Perspectives from Surgeon

Interested in attending a live or virtual event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science Summits. Click here to listen to our latest episodes!

Related Videos
David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Suresh Ramalingam, MD, and Chandler Park, MD
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Ben Levy, MD, and Yan Leyfman, MD
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
Related Content
FDA
June 10th 2024

FDA Grants Priority Review to Osimertinib for EGFR+ Stage III NSCLC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Lung cancer - stock.adobe.com
June 4th 2024

Nivolumab Plus Ipilimumab and Chemo Maintains OS Benefit in NSCLC

Jubilee Brown, MD, professor, director, Gynecologic Oncology, Atrium Health Levine Cancer Institute
May 13th 2024

Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

Tina Cascone, MD, PhD, of The University of Texas MD Anderson Cancer Center
June 3rd 2024

Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC

Aaron Lisberg, MD
June 3rd 2024

Dato-DXd Demonstrates Intracranial Activity in Advanced NSCLC With/Without Brain Metastases